On December 12, Fu Hong Hanlin announced that the company's self-developed innovative anti-PD-1 monoclonal antibody H drug Hans Form® combined with platinum-containing chemotherapy for adjuvant treatment after surgery. The marketing registration application for PD-L1 positive gastric cancer patients with surgical resection was accepted by the China Drug Administration and included in the priority review and approval process. Being included in the priority review means that the review period will be drastically shortened to 130 working days, marking an overall acceleration in the marketing process of H drug for perioperative treatment of gastric cancer. It is expected that H drug will become the first anti-PD-1 monoclonal antibody approved in this field in the world.

On December 12, Fu Hong Hanlin announced that the company's self-developed innovative anti-PD-1 monoclonal antibody H drug Hans Form® combined with platinum-containing chemotherapy for adjuvant treatment after surgery. The marketing registration application for PD-L1 positive gastric cancer patients with surgical resection was accepted by the China Drug Administration and included in the priority review and approval process. Being included in the priority review means that the review period will be drastically shortened to 130 working days, marking an overall acceleration in the marketing process of H drug for perioperative treatment of gastric cancer. It is expected that H drug will become the first anti-PD-1 monoclonal antibody approved in this field in the world.